Aisling M O'Riordan1, Niamh McGrath1,2, Farhana Sharif1,3, Nuala P Murphy2,4, Orla Franklin5, Sally Ann Lynch6,7, Michael J O'Grady8. 1. Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath, Ireland. 2. Department of Paediatric Endocrinology, Temple Street Children's University Hospital, Dublin 1, Ireland. 3. Department of Paediatrics, Royal College of Surgeons Ireland (RCSI), Dublin 2, Ireland. 4. UCD School of Medicine, University College Dublin, Dublin 4, Ireland. 5. Department of Paediatric Cardiology, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 6. UCD Academic Centre on Rare Diseases, University College Dublin, Dublin 4, Ireland. 7. Department of Clinical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 8. Department of Paediatrics, Midland Regional Hospital, Mullingar, Co. Westmeath, Ireland. michaelogrady@physicians.ie.
Abstract
Haploinsufficiency of the insulin-like growth factor-1 receptor (IGF1R) gene on chromosome 15q26.3 is associated with impaired prenatal and postnatal growth, developmental delay, dysmorphic features and skeletal abnormalities. Terminal deletions of chromosome 15q26 arising more proximally may also be associated with congenital heart disease, epilepsy, diaphragmatic hernia and renal anomalies. We report three additional cases of 15q26 terminal deletions with novel features which may further expand the spectrum of this rarely reported contiguous gene syndrome. Phenotypic features including neonatal lymphedema, aplasia cutis congenita and aortic root dilatation have not been reported previously. Similarly, laboratory features of insulin-like growth factor 1 (IGF-1) resistance are described, including markedly elevated IGF-1 of up to +4.7 SDS. In one patient, the elevated IGF-1 declined over time and this coincided with a period of spontaneous growth acceleration. CONCLUSION: Deletions of 15q26 are a potential risk factor for aortic root dilatation, neonatal lymphedema and aplasia cutis in addition to causing growth restriction. What is Known: • Terminal deletions of chromosome 15q26 are associated with impaired prenatal and postnatal growth, developmental delay, dysmorphic features and skeletal abnormalities. What is New: • Neonatal lymphedema, aplasia cutis congenita and aortic root dilatation have not been previously described in 15q26 terminal deletions and may represent novel features. • IGF-1 levels may be increased up to 4.7 SDS.
Haploinsufficiency of the insulin-like growth factor-1 receptor (IGF1R) gene on chromosome 15q26.3 is associated with impaired prenatal and postnatal growth, developmental delay, dysmorphic features and skeletal abnormalities. Terminal deletions of chromosome 15q26 arising more proximally may also be associated with congenital heart disease, epilepsy, diaphragmatic hernia and renal anomalies. We report three additional cases of 15q26 terminal deletions with novel features which may further expand the spectrum of this rarely reported contiguous gene syndrome. Phenotypic features including neonatal lymphedema, aplasia cutis congenita and aortic root dilatation have not been reported previously. Similarly, laboratory features of insulin-like growth factor 1 (IGF-1) resistance are described, including markedly elevated IGF-1 of up to +4.7 SDS. In one patient, the elevated IGF-1 declined over time and this coincided with a period of spontaneous growth acceleration. CONCLUSION: Deletions of 15q26 are a potential risk factor for aortic root dilatation, neonatal lymphedema and aplasia cutis in addition to causing growth restriction. What is Known: • Terminal deletions of chromosome 15q26 are associated with impaired prenatal and postnatal growth, developmental delay, dysmorphic features and skeletal abnormalities. What is New: • Neonatal lymphedema, aplasia cutis congenita and aortic root dilatation have not been previously described in 15q26 terminal deletions and may represent novel features. • IGF-1 levels may be increased up to 4.7 SDS.
Authors: D C M Veenma; H J Eussen; L C P Govaerts; S W K de Kort; R J Odink; C H Wouters; A C S Hokken-Koelega; A de Klein Journal: J Med Genet Date: 2009-12-02 Impact factor: 6.318
Authors: Marie J E Walenkamp; Sabine M P F de Muinck Keizer-Schrama; Marianne de Mos; Margot E Kalf; Hermine A van Duyvenvoorde; Annemieke M Boot; Sarina G Kant; Stefan J White; Monique Losekoot; Johan T Den Dunnen; Marcel Karperien; Jan M Wit Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: Yumiko Okubo; Ken Siddle; Helen Firth; Steve O'Rahilly; Louise C Wilson; Lionel Willatt; Toshiaki Fukushima; Shin-ichiro Takahashi; Clive J Petry; Tero Saukkonen; Richard Stanhope; David B Dunger Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: Wietske A Ester; Hermine A van Duyvenvoorde; Caroline C de Wit; Alexander J Broekman; Claudia A L Ruivenkamp; Lutgarde C P Govaerts; Jan M Wit; Anita C S Hokken-Koelega; Monique Losekoot Journal: J Clin Endocrinol Metab Date: 2009-10-28 Impact factor: 5.958
Authors: Martin Poot; Annemarie A Verrijn Stuart; Emma van Daalen; Andries van Iperen; Ellen van Binsbergen; Ron Hochstenbach Journal: Eur J Med Genet Date: 2013-04-16 Impact factor: 2.708
Authors: T Siebler; W Lopaczynski; C L Terry; S J Casella; P Munson; D D De Leon; L Phang; K J Blakemore; R C McEvoy; R I Kelley Journal: J Clin Endocrinol Metab Date: 1995-12 Impact factor: 5.958
Authors: Yuqin Luo; Min Shen; Yixi Sun; Yeqing Qian; Liya Wang; Jialing Yu; Junjie Hu; Fan Jin; Minyue Dong Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban Date: 2019-06-25
Authors: Muhammad M Rahman; Km Furkan Uddin; Nesreen K Al Jezawi; Noushad Karuvantevida; Hosneara Akter; Nushrat J Dity; Md Ashiquir Rahaman; Maksuda Begum; Md Atikur Rahaman; Md Abdul Baqui; Zeena Salwa; Serajul Islam; Marc Woodbury-Smith; Mohammed Basiruzzaman; Mohammed Uddin Journal: Mol Genet Genomic Med Date: 2019-09-01 Impact factor: 2.183